Last reviewed · How we verify

Norgesic — Competitive Intelligence Brief

Norgesic (acetylsalicylic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: centrally acting muscle relaxant with anticholinergic properties. Area: Immunology.

marketed centrally acting muscle relaxant with anticholinergic properties reticular formation (brain stem) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Norgesic (acetylsalicylic acid) — Endo. Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Norgesic TARGET acetylsalicylic acid Endo marketed centrally acting muscle relaxant with anticholinergic properties reticular formation (brain stem) 1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (centrally acting muscle relaxant with anticholinergic properties class)

  1. Endo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norgesic — Competitive Intelligence Brief. https://druglandscape.com/ci/acetylsalicylic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: